Pasireotide Treatment for Neuroendocrine Tumor

NCT ID: NCT02779257

Last Updated: 2022-03-04

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-30
• Study Completion Date: 2016-06-30

Brief Summary

Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.

Conditions

Gastro-enteropancreatic Neuroendocrine Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pasireotide

Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor

Group Type: EXPERIMENTAL

Pasireotide

Intervention Type: DRUG

Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.

Diazoxide

Intervention Type: DRUG

Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.

Interventions

Pasireotide

Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.

Intervention Type: DRUG

Diazoxide

Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Aged 18 years or older

2. Biopsy-proven (primary or metastatic lesion) metastatic neuroendocrine tumor of the gastrointestinal and pancreatic location with disease determined by CT scan or MRI

3. Patients with history of clinical syndrome symptoms (e.g. hypoglycemia)

4. Patients not controlled by treatment with currently available somatostatin analogues.

5. No evidence of significant liver disease:

• Serum bilirubin ≤1.5 x ULN
• INR < 1.3
• ALT and AST ≤ 3x ULN,
• Alkaline phosphatase ≤ 2.5 x ULN

6. Written informed consent obtained prior to treatment to be consistent with local regulatory requirements

7. Is suffering from a serious or life-threatening disease or condition

8. Does not have access to a comparable or satisfactory alternative treatment (i.e., comparable or satisfactory treatment is not available or does not exist)

9. Is not eligible for participation in any of the IMP's ongoing clinical trials or has recently completed a clinical trial that has been terminated and, after considering other options (e.g., trial extensions, amendments, etc.), the clinical team has determined that treatment is necessary and there are no other feasible alternatives for the patient

10. Meets any other relevant medical criteria for compassionate use of the investigational product

11. Is not being transferred from an ongoing clinical trial for which they are still eligible

12. There are meaningful human clinical data to support an assessment that the potential benefits to patient outweigh risks.

Exclusion Criteria

1. Patients with a known hypersensitivity to somatostatin analogs or any component of the pasireotide LAR or s.c. formulations.

2. Patients with abnormal coagulation (PT or aPTT elevated by 30% above normal limits).

3. Patients on continuous anticoagulation therapy. Patients who were on anticoagulant therapy must complete a washout period of at least 10 days and have confirmed normal coagulation parameters before study inclusion.

4. Patients currently using warfarin / warfarin derivatives

5. Patients with symptomatic cholelithiasis.

6. Patients who are not biochemically euthyroid. Patients with known history of hypothyroidism are eligible if they are on adequate and stable replacement thyroid hormone therapy for at least 3 months.

• QTcF at screening >450 msec in males, and > 460 msec in females.
• Family history of idiopathic sudden death
• Sustained or clinically significant cardiac arrhythmias
• Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block
• Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
• Family history of long QT syndrome
• Concomitant medications known to prolong the QT interval.
• Potassium < or = 3.5 mmol/L

8. Patients who have any severe and/or uncontrolled medical conditions :

• Uncontrolled diabetes as defined by HbA1c > 8%
• Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunodeficiency, including a positive HIV test result (ELISA and Western blot). An HIV test will not be required; however, previous medical history will be reviewed.
• Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with this study treatment.
• Life-threatening autoimmune and ischemic disorders.

9. Patients who have a history of another primary malignancy, with the exception of locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix. Patients who have had no evidence of disease from another primary cancer for 1 or more years are allowed to participate in the study.

10. Patients with history of liver disease, such as cirrhosis or chronic active hepatitis B or C

11. Presence of Hepatitis B surface antigen (HbsAg)

12. Presence of Hepatitis C antibody (anti-HCV)

13. History of, or current alcohol misuse/abuse within the past 12 months.

14. Known gallbladder or bile duct disease, acute or chronic pancreatitis

15. Patients with hypomagnesaemia (< 0.7 mmol/L)

16. Patients with a history of non-compliance to medical regimens

17. If the patient is a sexually active male he is excluded unless he agrees to use a condom during intercourse while taking pasireotide and for 3 months after stopping pasireotide medication. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

University of Maryland, Baltimore

OTHER

Sponsor Role: lead

Responsible Party

Kashif Munir

Assistant Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Kashif M Munir, MD

Role: PRINCIPAL_INVESTIGATOR

University of Maryland, Baltimore

References

Tirosh A, Stemmer SM, Solomonov E, Elnekave E, Saeger W, Ravkin Y, Nir K, Talmor Y, Shimon I. Pasireotide for malignant insulinoma. Hormones (Athens). 2016 Apr;15(2):271-276. doi: 10.14310/horm.2002.1639.

Reference Type: BACKGROUND

PMID: 26732164 (View on PubMed)

Other Identifiers

HP-00069513EU

Identifier Type: -

Identifier Source: org_study_id